Actis Oncology develops innovative therapies for cancer treatment.
Radiopharmaceutical mini-proteins with a $500M EV and $300M cash. Validated targets (Nectin-4, B7H3). The actinium isotope is manufactured only in the US — a structural moat against Chinese biosimilars. Clinical data is expected in Q1 2027; it could be worth $10B / $200 per share.